Brief: Aptose Receives Deficiency Letter From Nasdaq Listing Qualifications Department
22/07/2022 12:51
July 22 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE BIOSCIENCES INC - ON JULY 18, RECEIVED A DEFICIENCY
LETTER FROM NASDAQ LISTING QUALIFICATIONS DEPARTMENT OF NASDAQ
STOCK MARKET LLC
* APTOSE BIOSCIENCES - ON JULY 18 RECEIVED NOTICE OF
DELISTING OR
FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting